Since secondary GBM frequently harbor mutations in both, IDH1 and ATRX genes [43], future studies should address the toxicity of RTKi and selective PDGFRi (with and without TMZ) in cells with this relevant mutational background. This evidence concerns the gene IDH1 and glioblastoma.